Yamamoto, Noboru
Koyama, Takafumi
Shimizu, Toshio
Todaka, Akiko
Kawakami, Takeshi
Erzen, Damijan
Sarashina, Akiko
Li, Bin
Hou, Jianrui
Yamazaki, Kentaro http://orcid.org/0000-0001-6269-9345
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors
https://doi.org/10.1007/s00280-023-04527-6
Funding for this research was provided by:
Boehringer Ingelheim International GmbH
Article History
Received: 8 December 2022
Accepted: 19 March 2023
First Online: 4 May 2023
Change Date: 10 July 2023
Change Type: Update
Change Details: The original version is updated due to minor corrections and realignment of text.
Declarations
:
: Noboru Yamamoto reports receiving honoraria from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Ono Pharmaceutical, and Sysmex; consulting/advisory fees from Boehringer Ingelheim, Cimic, Eisai, Otsuka, and Takeda Pharmaceuticals; and research funding (institution) from Astellas Pharma, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Chiome Bioscience, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly & Co, Genmab, GlaxoSmithKline, Janssen Pharma, Kyowa Hakko Kirin, Merck Sharp & Dohme, Merck, Novartis, Ono Pharmaceutical, Otsuka, Pfizer, Quintiles, Sumitomo Dainippon, Taiho Pharmaceutical, Takeda Pharmaceuticals, Shionogi, KAKEN, and TORAY. Takafumi Koyama reported receiving personal fees from Chugai and Sysmex and grants from PACT Pharma, Chugai, Novartis, Eli Lilly and Company, Pfizer, Loxo Oncology, and Takeda Oncology. Toshio Shimizu declares grants from Novartis, Eli Lilly and Company, AbbVie, Daiichi-Sankyo, Eisai, Bristol-Myers Squibb, AstraZeneca, Pfizer, Loxo Oncology, Takeda Oncology, Incyte, Chordia Therapeutics, 3D-Medicine, Symbio Pharmaceuticals, PharmaMar, and Astellas. Akiko Todaka received honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, Yakult Honsha and Nihon Servier. Takeshi Kawakami received honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, and Bristol-Myers Squibb. Damijan Erzen, Akiko Sarashina, Bin Li and Jianrui Hou report being employed by Boehringer Ingelheim. Kentaro Yamazaki reported receiving honoraria from Chugai Pharma, Daiichi Sankyo, Yakult Honsha, Takeda, Bayer, Merck Serono, Taiho Pharmaceutical, Lilly, Sanofi, Ono Pharmaceutical, MSD, Bristol Myers Squibb; and institutional research funding from Taiho Pharmaceutical.